1
|
Salga M, Samuel SG, Tseng HW, Gatin L, Girard D, Rival B, Barbier V, Bisht K, Shatunova S, Debaud C, Winkler IG, Paquereau J, Dinh A, Genêt G, Kerever S, Abback PS, Banzet S, Genêt F, Lévesque JP, Alexander KA. Bacterial Lipopolysaccharides Exacerbate Neurogenic Heterotopic Ossification Development. J Bone Miner Res 2023; 38:1700-1717. [PMID: 37602772 DOI: 10.1002/jbmr.4905] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Revised: 07/24/2023] [Accepted: 08/15/2023] [Indexed: 08/22/2023]
Abstract
Neurogenic heterotopic ossifications (NHO) are heterotopic bones that develop in periarticular muscles after severe central nervous system (CNS) injuries. Several retrospective studies have shown that NHO prevalence is higher in patients who suffer concomitant infections. However, it is unclear whether these infections directly contribute to NHO development or reflect the immunodepression observed in patients with CNS injury. Using our mouse model of NHO induced by spinal cord injury (SCI) between vertebrae T11 to T13 , we demonstrate that lipopolysaccharides (LPS) from gram-negative bacteria exacerbate NHO development in a toll-like receptor-4 (TLR4)-dependent manner, signaling through the TIR-domain-containing adapter-inducing interferon-β (TRIF/TICAM1) adaptor rather than the myeloid differentiation primary response-88 (MYD88) adaptor. We find that T11 to T13 SCI did not significantly alter intestinal integrity nor cause intestinal bacteria translocation or endotoxemia, suggesting that NHO development is not driven by endotoxins from the gut in this model of SCI-induced NHO. Relevant to the human pathology, LPS increased expression of osteoblast markers in cultures of human fibro-adipogenic progenitors isolated from muscles surrounding NHO biopsies. In a case-control retrospective study in patients with traumatic brain injuries, infections with gram-negative Pseudomonas species were significantly associated with NHO development. Together these data suggest a functional association between gram-negative bacterial infections and NHO development and highlights infection management as a key consideration to avoid NHO development in patients. © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Collapse
Affiliation(s)
- Marjorie Salga
- Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, Australia
- University of Versailles Saint Quentin en Yvelines, END:ICAP U1179 INSERM, UFR Simone Veil-Santé, Montigny le Bretonneux, France
- UPOH (Unité Péri Opératoire du Handicap), Physical and Rehabilitation Medicine Department, Raymond-Poincaré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Garches, France
| | - Selwin G Samuel
- Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, Australia
- Department of Oral Pathology and Microbiology, Saveetha Dental College and Hospitals, Chennai, India
| | - Hsu-Wen Tseng
- Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, Australia
| | - Laure Gatin
- University of Versailles Saint Quentin en Yvelines, END:ICAP U1179 INSERM, UFR Simone Veil-Santé, Montigny le Bretonneux, France
- UPOH (Unité Péri Opératoire du Handicap), Physical and Rehabilitation Medicine Department, Raymond-Poincaré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Garches, France
- Department of Orthopedic Surgery, Raymond Poincaré Hospital, AP-HP, Garches, France
| | - Dorothée Girard
- Institut de Recherche Biomédicale des Armées (IRBA), INSERM UMR-MD 1197, Clamart, France
| | - Bastien Rival
- Institut de Recherche Biomédicale des Armées (IRBA), INSERM UMR-MD 1197, Clamart, France
| | - Valérie Barbier
- Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, Australia
| | - Kavita Bisht
- Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, Australia
| | - Svetlana Shatunova
- Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, Australia
| | - Charlotte Debaud
- University of Versailles Saint Quentin en Yvelines, END:ICAP U1179 INSERM, UFR Simone Veil-Santé, Montigny le Bretonneux, France
| | - Ingrid G Winkler
- Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, Australia
| | - Julie Paquereau
- UPOH (Unité Péri Opératoire du Handicap), Physical and Rehabilitation Medicine Department, Raymond-Poincaré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Garches, France
| | - Aurélien Dinh
- Department of Infectious Diseases, Raymond Poincaré Hospital, AP-HP, Garches, France
| | - Guillaume Genêt
- University of Versailles Saint Quentin en Yvelines, END:ICAP U1179 INSERM, UFR Simone Veil-Santé, Montigny le Bretonneux, France
| | - Sébastien Kerever
- Department of Anesthesiology and Critical Care, Lariboisière University Hospital, AP-HP, Paris, France
| | - Paer-Sélim Abback
- Department of Anesthesiology and Critical Care, Beaujon Hospital, DMU Parabol, AP-HP, Clichy, France
| | - Sébastien Banzet
- Institut de Recherche Biomédicale des Armées (IRBA), INSERM UMR-MD 1197, Clamart, France
| | - François Genêt
- University of Versailles Saint Quentin en Yvelines, END:ICAP U1179 INSERM, UFR Simone Veil-Santé, Montigny le Bretonneux, France
- UPOH (Unité Péri Opératoire du Handicap), Physical and Rehabilitation Medicine Department, Raymond-Poincaré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Garches, France
| | - Jean-Pierre Lévesque
- Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, Australia
| | - Kylie A Alexander
- Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, Australia
| |
Collapse
|
2
|
Gueguen J, Girard D, Rival B, Fernandez J, Goriot ME, Banzet S. Spinal cord injury dysregulates fibro-adipogenic progenitors miRNAs signaling to promote neurogenic heterotopic ossifications. Commun Biol 2023; 6:932. [PMID: 37700159 PMCID: PMC10497574 DOI: 10.1038/s42003-023-05316-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Accepted: 09/01/2023] [Indexed: 09/14/2023] Open
Abstract
Neurogenic heterotopic ossifications are intramuscular bone formations developing following central nervous system injury. The pathophysiology is poorly understood and current treatments for this debilitating condition remain unsatisfying. Here we explored the role of miRNAs in a clinically relevant mouse model that combines muscle and spinal cord injury, and in patients' cells. We found an osteo-suppressive miRNAs response in injured muscle that was hindered when the spinal cord injury was associated. In isolated fibro-adipogenic progenitors from damaged muscle (cells at the origin of ossification), spinal cord injury induced a downregulation of osteo-suppressive miRNAs while osteogenic markers were overexpressed. The overexpression of selected miRNAs in patient's fibro-adipogenic progenitors inhibited mineralization and osteo-chondrogenic markers in vitro. Altogether, we highlighted an osteo-suppressive mechanism involving multiple miRNAs in response to muscle injury that prevents osteogenic commitment which is ablated by the neurologic lesion in heterotopic ossification pathogenesis. This provides new research hypotheses for preventive treatments.
Collapse
Affiliation(s)
- Jules Gueguen
- Institut de Recherche Biomédicale des Armées, 92140, Clamart, France
- INSERM UMR-MD-1197, 92140, Clamart, France
| | - Dorothée Girard
- Institut de Recherche Biomédicale des Armées, 92140, Clamart, France
- INSERM UMR-MD-1197, 92140, Clamart, France
| | - Bastien Rival
- Institut de Recherche Biomédicale des Armées, 92140, Clamart, France
- INSERM UMR-MD-1197, 92140, Clamart, France
| | - Juliette Fernandez
- Institut de Recherche Biomédicale des Armées, 92140, Clamart, France
- INSERM UMR-MD-1197, 92140, Clamart, France
| | - Marie-Emmanuelle Goriot
- Institut de Recherche Biomédicale des Armées, 92140, Clamart, France
- INSERM UMR-MD-1197, 92140, Clamart, France
| | - Sébastien Banzet
- Institut de Recherche Biomédicale des Armées, 92140, Clamart, France.
- INSERM UMR-MD-1197, 92140, Clamart, France.
| |
Collapse
|
3
|
Lorenzini B, Peltzer J, Goulinet S, Rival B, Lataillade JJ, Uzan G, Banzet S, Mauduit P. Producing vesicle-free cell culture additive for human cells extracellular vesicles manufacturing. J Control Release 2023; 355:501-514. [PMID: 36764527 DOI: 10.1016/j.jconrel.2023.01.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Revised: 01/22/2023] [Accepted: 01/29/2023] [Indexed: 02/12/2023]
Abstract
A new paradigm has emerged recently, which consists in shifting from cell therapy to a more flexible acellular "extracellular vesicle (EV) therapy" approach, thereby opening a new and promising field in nanomedicine. Important technical limitations have still to be addressed for the large-scale production of clinical-grade EV. Cells are cultured in media supplemented with human platelet lysate (hPL) (xenogenic-free) or GMP-grade fetal calf serum (FCS). However, these additives contain high amounts of EV that cannot be separated from cell-secreted -EV. Therefore, cells are generally maintained in additive-free medium during the EV secretion phase, however this can substantially limit their survival. In the present work, we developed a method to prepare vesicle-free hPL (EV-free hPL) or vesicle-free FCS (EV-free FCS) using tangential flow filtration (TFF). We show a very efficient EV depletion (>98%) for both pure hPL and FCS, with a highly conserved protein content. Culture medium containing our EV-free additives supported the survival of human bone marrow MSC (BM-MSC). MSC could survive at least 216 h, their conditioned medium being collected and changed every 72 h. Both the cell survival and the cumulative EV production were substantially higher than in the starving conditions classically used for EV production. In EV-free hPL containing medium, we show that purified EV kept their morphologic and molecular characteristics throughout the production. Finally, we tested our additives with 3 other cell types, human primary Endothelial Colony Forming Cells (ECFC) and two non-adherent human cell lines, Jurkat and THP-1. We confirmed that both EV-free hPL and FCS were able to maintain cell survival and EV production for at least 216 h. Our method provides therefore a new option to help producing large amounts of EV from virtually any mammalian cells, particularly those that do not tolerate starvation. This method can apply to any animal serum for research and development purpose. Moreover, EV-free hPL is clinical-grade compatible and allows preparing xenobiotic-free media for massive therapeutic EV production in both 2D (cell plates) and 3D (bioreactor) setting.
Collapse
Affiliation(s)
- Bileyle Lorenzini
- INSERM UMR-MD-1197 « Interactions cellules souches-niches: physiologie, tumeurs et réparation tissulaire » Institut André Lwoff/Université Paris-Saclay, Hôpital Paul Brousse, 14, Avenue Paul-Vaillant Couturier, 94807 Villejuif, France
| | - Juliette Peltzer
- INSERM UMR-MD-1197 « Interactions cellules souches-niches: physiologie, tumeurs et réparation tissulaire » Institut André Lwoff/Université Paris-Saclay, Hôpital Paul Brousse, 14, Avenue Paul-Vaillant Couturier, 94807 Villejuif, France; Institut de Recherche Biomédicale des Armées, Centre de Transfusion Sanguine des Armées, 1 rue Lt Raoul Batany, 92140 Clamart, France
| | - Sylvie Goulinet
- INSERM UMR-MD-1197 « Interactions cellules souches-niches: physiologie, tumeurs et réparation tissulaire » Institut André Lwoff/Université Paris-Saclay, Hôpital Paul Brousse, 14, Avenue Paul-Vaillant Couturier, 94807 Villejuif, France
| | - Bastien Rival
- INSERM UMR-MD-1197 « Interactions cellules souches-niches: physiologie, tumeurs et réparation tissulaire » Institut André Lwoff/Université Paris-Saclay, Hôpital Paul Brousse, 14, Avenue Paul-Vaillant Couturier, 94807 Villejuif, France; Institut de Recherche Biomédicale des Armées, Centre de Transfusion Sanguine des Armées, 1 rue Lt Raoul Batany, 92140 Clamart, France
| | | | - Georges Uzan
- INSERM UMR-MD-1197 « Interactions cellules souches-niches: physiologie, tumeurs et réparation tissulaire » Institut André Lwoff/Université Paris-Saclay, Hôpital Paul Brousse, 14, Avenue Paul-Vaillant Couturier, 94807 Villejuif, France
| | - Sébastien Banzet
- INSERM UMR-MD-1197 « Interactions cellules souches-niches: physiologie, tumeurs et réparation tissulaire » Institut André Lwoff/Université Paris-Saclay, Hôpital Paul Brousse, 14, Avenue Paul-Vaillant Couturier, 94807 Villejuif, France; Institut de Recherche Biomédicale des Armées, Centre de Transfusion Sanguine des Armées, 1 rue Lt Raoul Batany, 92140 Clamart, France; Centre de Transfusion Sanguine des Armées, 1 rue Lt Raoul Batany, 92140 Clamart, France.
| | - Philippe Mauduit
- INSERM UMR-MD-1197 « Interactions cellules souches-niches: physiologie, tumeurs et réparation tissulaire » Institut André Lwoff/Université Paris-Saclay, Hôpital Paul Brousse, 14, Avenue Paul-Vaillant Couturier, 94807 Villejuif, France.
| |
Collapse
|
4
|
Peltzer J, Goulinet S, Lorenzini B, Rival B, Trouillas M, Banzet S, Lataillade J, Uzan G, Mauduit P. Production and use of extracellular vesicles-depleted human platelet lysate to improve large, clinical grade-compatible production of therapeutic human cell-derived extracellular vesicles. Cytotherapy 2020. [DOI: 10.1016/j.jcyt.2020.03.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
5
|
Boiteux-Jurain M, Rival B, Netillard C, Tissot E. Impact des antipsychotiques injectables à action prolongée (rispéridone, palipéridone) sur le taux de réhospitalisation : analyse coût-efficacité. Eur Psychiatry 2015. [DOI: 10.1016/j.eurpsy.2015.09.310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Les antispychotiques à action prolongée (APAP) ont démontré un intérêt clinique par rapport à la voie orale . Suite aux recommandations 2014 , il nous a paru intéressant d’effectuer une étude coût-efficacité APAP versus antipsychotiques per os. Durant la période du 01/01/2013 au 30/06/2014, les patients schizophrènes bénéficiant d’une instauration d’APAP (palipéridone, rispéridone injectable) ou de rispéridone per os ont été inclus. Les taux de réhospitalisation dans ces deux groupes sont calculés à 6 mois (m6) et à 12 mois (m12) puis comparés. Les coûts de prise en charge calculés sont les coûts médicaux directs: nombre de journées d’hospitalisation et médicament antipsychotique. 238 patients sont inclus dans l’étude avec 162 patients pour la période de m0 à m6 (76 perdus de vus) et 151 patients pour la période de m0 à m12 (87 perdus de vus). Nous n’observons pas de différence significative entre le groupe APAP versus rispéridone per os sur les taux de réhospitalisation à 6 mois (33 % APAP versus 44 % rispéridone per os) et à 12 mois (46 % versus 60 %). Le nombre médian de journées d’hospitalisation est moins élevé avec chaque sous-groupe d’APAP par rapport à la rispéridone per os pour les deux périodes. Concernant l’analyse économique, le coût médian en médicaments est plus bas pour le groupe rispéridone per os que pour les APAP mais, a contrario, le coût médian en hospitalisation est plus important pour le groupe rispéridone per os à 6 mois et à 12 mois. Une différence en faveur du groupe APAP de 2800 € est observée à m6 et de 4700 € à m12. Même s’il n’existe pas de différence significative sur le taux de réhospitalisation, le groupe APAP représente une stratégie moins onéreuse malgré le coût d’une injection plus important que celui de la rispéridone per os.
Collapse
|
6
|
Sauron C, Jouvet P, Pinard G, Goudreault D, Martin B, Rival B, Moussa A. Using isopropyl alcohol impregnated disinfection caps in the neonatal intensive care unit can cause isopropyl alcohol toxicity. Acta Paediatr 2015; 104:e489-93. [PMID: 26109465 DOI: 10.1111/apa.13099] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/23/2015] [Accepted: 06/18/2015] [Indexed: 11/29/2022]
Abstract
AIM The safety of SwabCap alcohol impregnated disinfection caps was questioned in our unit because of malfunctions in luer access valves. We examined whether SwabCaps affected the integrity of two luer access valves and were associated with alcohol injected into the lines. METHODS Our bench test study included seven circuits using SmartSite or CARESITE valves exposed to two environmental temperatures. Passive circuits consisted of a 96-hour contact system using SwabCap without other interventions. Active circuits consisted of nine sham injections during a 24-hour period, with the SwabCap replaced after each injection. The active control circuit used isopropyl alcohol impregnated pads to disinfect valves. Isopropyl alcohol was measured at the extremity of all active circuits by gas chromatography. RESULTS The visual appearance of all SmartSite valves and 67% of the CARESITE valves was changed by SwabCap use. The mean isopropyl alcohol dosages were 52 mmol/L in the SmartSite and 8 mmol/L in the CARESITE at room temperature and 73 and 7 mmol/L, respectively, at 35°C. No alcohol was found in the control circuit. CONCLUSION The SwabCap altered the valves' appearance and allowed significant amounts of isopropyl alcohol to be injected. It should not be used for neonates without further research.
Collapse
Affiliation(s)
- Charlotte Sauron
- Neonatology; CHU Sainte-Justine; University of Montreal; Montreal QC Canada
- Neonatology; Hôpital Femme-Mère-Enfant; Hospices Civils de Lyon; Bron France
| | - Philippe Jouvet
- Pediatric Intensive Care; CHU Sainte-Justine; Montreal QC Canada
| | - Geneviève Pinard
- Quality, Security and Risk Counsel; CHU Sainte-Justine; Montreal QC Canada
| | | | | | - Bastien Rival
- Specialized Biochemistry Laboratory; CHU Sainte-Justine; Montreal QC Canada
| | - Ahmed Moussa
- Neonatology; CHU Sainte-Justine; University of Montreal; Montreal QC Canada
| |
Collapse
|
7
|
Gauthier AS, Rival B, Sahler J, Fagnoni-Legat C, Limat S, Guillaume Y, Delbosc B. Développement galénique et analytique d’un collyre à base de tacrolimus 0,06 %. J Fr Ophtalmol 2013; 36:408-13. [DOI: 10.1016/j.jfo.2012.03.019] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2011] [Revised: 03/16/2012] [Accepted: 03/22/2012] [Indexed: 10/27/2022]
|